Navigation Links
Male contraception breakthroughs to be presented, Seattle Sept. 27-28
Date:9/21/2007

Seattle will be the place to be on September 27 and 28, when male contraception researchers from the U.S. and overseas gather to present their news. The second Future of Male Contraception conference sponsored by the National Institute of Child Health and Human Development, CONRAD, the World Health Organization, and the University of Washington will be at Seattles Edgewater Hotel overlooking the Puget Sound. Registration is free of charge.

Here is a sample of the news to be announced at the conference:

  • a new compound that can be taken orally (Columbia University, Retinoic acid alpha receptor inhibitor)

  • 3-month and 6-month results in men for the Intra Vas Device, a vasectomy alternative (Shepherd Medical Company)

  • Gamendazole: how it works in animals, and finding the right dose (University of Kansas and University of Minnesota)

  • clinical proof-of-concept studies on testosterone alternatives for use in a "male pill" (GTx, Inc., SARMs)

  • evidence of public demand, including survey results (International Male Contraception Coalition)

Many other teams will present late-breaking news during the poster session, 7-9 pm September 27th.

For further information, see the conference website: http://www.futureofmalecontraception.com


'/>"/>

Contact: Donna Perkins
919-967-2399 x320
Male Contraception Information Project
Source:Eurekalert

1

GOOD

Page: 1

Related biology news :

1. Hormonal male contraception reversible after few months for all men
2. Emergency contraception fails to halt abortions
3. Male contraception: One door opens, another closes
4. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
5. Traumas like Sept. 11 make brains more reactive to fear

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...t keep weakened and flabby arteries from collapsin..., those stents are no longer needed -- once the ar...Previously, doctors had no choice but to leave the... University,s Department of Biomedical Engineering... that carries drugs where they,re needed, then dis...
(Date:11/24/2009)...UGE Antarctica has long held secrets of the earth...ently, there has been very little information on t...s of ice for millions of years. Now, a team of res...ve been funded to the tune of $10 million dollars ... to the bottom of things literally. These scienti...
(Date:11/23/2009)...New research presents strong evidence that the "sy...utdoor traffic-related pollution and indoor endoto...or the other exposure alone. , Environmental h...UC) College of Medicine have shown that children e...icles and indoor endotoxin during early life are s...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 1ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 2ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 3ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 4ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 5ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 6ICL Reports Continued Sequential Improvement for Third Quarter of 2009 62011 7Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 1Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 2Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 3Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 62008 1Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 62008 2Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 62008 3
...AMBRIDGE, Mass. (April 2, 2009) Whitehead Institu...ifiable prion proteins in yeast and have further c...f both beneficial and detrimental traits. , "The ...al are they evolved to be prions, or are they alw...," says Randal Halfmann, a research assistant in W...
...New diseases directly affect human survival and fo...bs. Leaf-cutting ants, one of a few groups of soci...t material to fertilize their underground fungal g... Smithsonian show that both the ants and their fun...t inside leaves, thus ensuring the health of their...
...AMBRIDGE, Mass.--Each year, hundreds of thousands ...rmic needles that penetrate too far under their sk...lleagues aims to prevent this from happening by ke...urely mechanical, is based on concepts borrowed fr... needle containing a filament that acts as a guide...
Other Biology News:Redefining what it means to be a prion 2Redefining what it means to be a prion 3Food security for leaf-cutting ants: Workers and their fungus garden reject endophyte invaders 2MIT: Novel needle could cut medical complications 2
(Date:11/25/2009)..., Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd...ines, announced today that it executed,a joint ven...Vaccine,Technology Co., Ltd. (Sinovac Dalian). The...ize human-use vaccines. Sinovac will contribute it...rcializing world-class vaccines; the,other party w...
(Date:11/24/2009)...n German . , Whether it,s CD packaging, con...Frequency Identification) are increasingly finding...le to label objects or goods and identify them aut...nner can read and process the data contained in th...r production conditions of up to 100 degrees Celsi...
(Date:11/24/2009)...New York investment bank KTA Capital,s client Neur...6.7 mil convertible note private placement with a ... was arranged by KTA Capital as Neuren,s exclusive... New York (PRWEB) November 23, 2009 -- The i...LC ("KTA Capital") has announced that it...
(Date:11/24/2009)...EYKJAVIK, Iceland, November 24 /PRNewswire-FirstCa... announced that it has received notice from,the Na...mmon stock will be,suspended as of November 30, 20...ties and Exchange Commission, which will remove de... the company files an appeal to the Nasdaq,Listing...
Breaking Biology Technology:Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3
...lcers each year in the US, PRINCETON, N.J., March...), provider of advanced wound care products,announ... the clinical usage,of its newly released MEDIHONE...mum Honey presented at the annual American Profess...ld the second week in March in Forth,Worth, Texas,...
...aunch..., WAYLAND, Mass., March 20 Tourtellotte ...linical trials software, announces the,launch of i...rm for phase,II-IV studies. Trident,s unique param...of legacy IVRS technologies and promises to delive...nd ease-of-use to the straining,global clinical IV...
...nc., a,pioneer in drug discovery from marine micro...begun in a Phase 1b study evaluating the vascular,...h standard chemotherapy,in patients with non-small...ositive outcomes in a Phase 1 single-agent clinica...armacodynamics (PK/PD) and efficacy of NPI-2358,in...
Other Biology Technology:Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA 2Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA 3Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA 4Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data 2Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data 3
Chicken Anti-HOXC11 Polyclonal Antibody, Unconjugated from ProSci, Inc
Chicken Anti-HOXC11 Polyclonal Antibody, Unconjugated from ProSci, Inc
Goat Anti-NIR1 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-NeuroD 6 Antibody, Unconjugated from CHEMICON
Biology Products: